If you have been NEWLY DIAGNOSED START HERE
On November 4th, 2016, in collaboration with UNC Lineberger and Lung Cancer Initiative of NC, GRACE presented 'Not Your Father's Squamous Lung Cancer'. Our third presentation discusses future directions in treatment, with Chad Pecot, MD.
For our 16th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss ALK rearrangements, what they are who has them.
On November 4th, 2016, in collaboration with UNC Lineberger and Lung Cancer Initiative of NC, GRACE presented 'Not Your Father's Squamous Lung Cancer'. In this 2nd video of the series, Jared Weiss, MD joins us to discuss currently available treatment options.
For our 15th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss treating later stage small cell lung cancer.
On November 4th, 2016, in collaboration with UNC Lineberger and Lung Cancer Initiative of NC, GRACE presented 'Not Your Father's Squamous Lung Cancer'. In this first video of the series, Dr. Chad Pecot, MD joins us to discuss 'What is squamous lung cancer?'
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce John Cherol, EGFR patient.
You may have noticed some frustrating server issues with GRACE these past few days. Our true apologies – we are working diligently with our provider...
You may have noticed some frustrating server issues with GRACE these past few days. Our true apologies – we are working diligently with our provider...
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce Sara Whitlock, RET + patient.
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.
Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".
Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock